Cargando…
Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells
Bcl-2 family protein is an important factor in regulating apoptosis and is associated with cancer. The anti-apoptotic proteins of Bcl-2 family, such as Bcl-2, are overexpression in numerous tumors, and contribute to cancer formation, development, and therapy resistance. Therefore, Bcl-2 is a promisi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478794/ https://www.ncbi.nlm.nih.gov/pubmed/31057406 http://dx.doi.org/10.3389/fphar.2019.00391 |
_version_ | 1783413214401265664 |
---|---|
author | Wen, Mei Deng, Zhen-ke Jiang, Shi-long Guan, Yi-di Wu, Hai-zhou Wang, Xin-luan Xiao, Song-shu Zhang, Yi Yang, Jin-ming Cao, Dong-sheng Cheng, Yan |
author_facet | Wen, Mei Deng, Zhen-ke Jiang, Shi-long Guan, Yi-di Wu, Hai-zhou Wang, Xin-luan Xiao, Song-shu Zhang, Yi Yang, Jin-ming Cao, Dong-sheng Cheng, Yan |
author_sort | Wen, Mei |
collection | PubMed |
description | Bcl-2 family protein is an important factor in regulating apoptosis and is associated with cancer. The anti-apoptotic proteins of Bcl-2 family, such as Bcl-2, are overexpression in numerous tumors, and contribute to cancer formation, development, and therapy resistance. Therefore, Bcl-2 is a promising target for drug development, and several Bcl-2 inhibitors are currently undergoing clinical trials. In this study, we carried out a QSAR-based virtual screening approach to develop potential Bcl-2 inhibitors from the SPECS database. Surface plasmon resonance (SPR) binding assay was performed to examine the interaction between Bcl-2 protein and the screened inhibitors. After that, we measured the anti-tumor activities of the 8 candidate compounds, and found that compound M1 has significant cytotoxic effect on breast cancer cells. We further proved that compound M1 downregulated Bcl-2 expression and activated apoptosis by inducing mitochondrial dysfunction. In conclusion, we identified a novel Bcl-2 inhibitor by QSAR screening, which exerted significant cytotoxic activity in breast cancer cells through inducing mitochondria-mediated apoptosis. |
format | Online Article Text |
id | pubmed-6478794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64787942019-05-03 Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells Wen, Mei Deng, Zhen-ke Jiang, Shi-long Guan, Yi-di Wu, Hai-zhou Wang, Xin-luan Xiao, Song-shu Zhang, Yi Yang, Jin-ming Cao, Dong-sheng Cheng, Yan Front Pharmacol Pharmacology Bcl-2 family protein is an important factor in regulating apoptosis and is associated with cancer. The anti-apoptotic proteins of Bcl-2 family, such as Bcl-2, are overexpression in numerous tumors, and contribute to cancer formation, development, and therapy resistance. Therefore, Bcl-2 is a promising target for drug development, and several Bcl-2 inhibitors are currently undergoing clinical trials. In this study, we carried out a QSAR-based virtual screening approach to develop potential Bcl-2 inhibitors from the SPECS database. Surface plasmon resonance (SPR) binding assay was performed to examine the interaction between Bcl-2 protein and the screened inhibitors. After that, we measured the anti-tumor activities of the 8 candidate compounds, and found that compound M1 has significant cytotoxic effect on breast cancer cells. We further proved that compound M1 downregulated Bcl-2 expression and activated apoptosis by inducing mitochondrial dysfunction. In conclusion, we identified a novel Bcl-2 inhibitor by QSAR screening, which exerted significant cytotoxic activity in breast cancer cells through inducing mitochondria-mediated apoptosis. Frontiers Media S.A. 2019-04-17 /pmc/articles/PMC6478794/ /pubmed/31057406 http://dx.doi.org/10.3389/fphar.2019.00391 Text en Copyright © 2019 Wen, Deng, Jiang, Guan, Wu, Wang, Xiao, Zhang, Yang, Cao and Cheng. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wen, Mei Deng, Zhen-ke Jiang, Shi-long Guan, Yi-di Wu, Hai-zhou Wang, Xin-luan Xiao, Song-shu Zhang, Yi Yang, Jin-ming Cao, Dong-sheng Cheng, Yan Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells |
title | Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells |
title_full | Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells |
title_fullStr | Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells |
title_full_unstemmed | Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells |
title_short | Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells |
title_sort | identification of a novel bcl-2 inhibitor by ligand-based screening and investigation of its anti-cancer effect on human breast cancer cells |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478794/ https://www.ncbi.nlm.nih.gov/pubmed/31057406 http://dx.doi.org/10.3389/fphar.2019.00391 |
work_keys_str_mv | AT wenmei identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells AT dengzhenke identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells AT jiangshilong identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells AT guanyidi identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells AT wuhaizhou identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells AT wangxinluan identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells AT xiaosongshu identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells AT zhangyi identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells AT yangjinming identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells AT caodongsheng identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells AT chengyan identificationofanovelbcl2inhibitorbyligandbasedscreeningandinvestigationofitsanticancereffectonhumanbreastcancercells |